---
cssClass:
- wide
tags:
  - ðŸ§ª
---

# `Title:` [[PROTAC]]
--- 

- What led me here: [[Molecular Glues]]

Inlinks
```dataview 
list from [[#this.file.name]] and !outgoing([[# this.file.name]]) 
```

# PROTAC in Drug Therapies

PROTAC (PROteolysis TArgeting Chimeras) is a novel therapeutic strategy that involves the targeted degradation of specific proteins. PROTACs are bifunctional molecules that bind to the target protein and an E3 ubiquitin ligase, leading to the ubiquitination and subsequent degradation of the target protein by the proteasome.

## Overview

PROTAC technology represents a paradigm shift in drug development. Traditional drugs function by inhibiting the activity of target proteins, whereas PROTACs work by inducing the degradation of target proteins. This approach has the potential to target "undruggable" proteins, i.e., proteins that cannot be inhibited by traditional small molecule drugs.

## Mechanism of Action

PROTACs work by recruiting an E3 ubiquitin ligase to a specific target protein. The PROTAC molecule has two binding sites: one for the target protein and one for the E3 ligase. Once the PROTAC molecule brings the E3 ligase into proximity with the target protein, the E3 ligase tags the target protein with ubiquitin molecules. This "ubiquitination" signals the proteasome to degrade the target protein.

## Applications

PROTACs have potential applications in a wide range of diseases, including cancer, neurodegenerative diseases, and infectious diseases. By degrading disease-causing proteins, PROTACs can potentially reverse the pathological processes underlying these diseases.

## Advantages and Limitations

PROTACs offer several advantages over traditional drugs, including the ability to target "undruggable" proteins, the potential for greater potency, and the ability to achieve sustained effects with intermittent dosing. However, PROTACs also face several challenges, including the need for intracellular delivery, potential off-target effects, and the possibility of resistance development.

## See Also

- [Drug Development](https://en.wikipedia.org/wiki/Drug_development)
- [Proteasome](https://en.wikipedia.org/wiki/Proteasome)
- [Ubiquitin](https://en.wikipedia.org/wiki/Ubiquitin)

## References

- Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001). Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proceedings of the National Academy of Sciences, 98(15), 8554-8559.
- Lai, A. C., & Crews, C. M. (2017). Induced protein degradation: an emerging drug discovery paradigm. Nature Reviews Drug Discovery, 16(2), 101-114.
- Bondeson, D. P., Mares, A., Smith, I. E., Ko, E., Campos, S., Miah, A. H., ... & Crew, A. P. (2015). Catalytic in vivo protein knockdown by small-molecule PROTACs. Nature chemical biology, 11(8), 611-617.